Fernando Alegre

Fernando Alegre

Auto-generated profile, based on publicly available information

Fernando Alegre

Department of Pharmacology, Faculty of Medicine, University of Valencia-CIBERehd, Valencia, Spain

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2017 in Seminars in Liver Disease
Verified
Journal Article
Closed access
PDF file
FAFernando Alegre
Fernando Alegre
PPPablo Pelegrin
Pablo Pelegrin
AFAriel E. Feldstein
Ariel E. Feldstein
Cell death and inflammation are two central elements in the development of liver fibrosis. Inflammasomes are intracellular multiprotein complexes expressed in both hepatocytes and nonparenchymal cells in the liver that are key regulators of inflammation and cell fate. They respond to cellular danger signals by activating caspase 1, releasing the proinflammatory cytokines IL-1β and IL-18, as well as initiating a novel pathway of programmed cell death termed “pyroptosis.” These processes can initiate and perpetuate an abnormal wound-healing response with the principle cellular target being the activation of hepatic stellate cells. From the various inflammasomes, the NLRP3 inflammasome has been increasingly implicated in the pathogenesis of chronic inflammatory liver diseases, including nonalcoholic steatohepatitis, a disease process that is soaring and has evolved as a primary cause of liver fibrosis and need for liver transplantation. In this review, the authors highlight the growing evidence for both indirect and direct effects of inflammasomes in triggering liver fibrosis as well as potential novel targets for antifibrotic therapies.

17 September 2019 in Gut
Verified
Journal Article
Closed access
PDF file
AMAlberto Martí-Rodrigo
Alberto Martí-Rodrigo
FAFernando Alegre
Fernando Alegre
ÁMÁngela B Moragrega
Ángela B Moragrega
FGFrancisco García García
Francisco García García
PMPablo Martí-Rodrigo
Pablo Martí-Rodrigo
ABAna Blas-García
Ana Blas-García
Objective Liver fibrosis constitutes a major health problem worldwide due to its rapidly increasing prevalence and the lack of specific and effective treatments. Growing evidence suggests that signalling through cytokine-activated Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathways regulates liver fibrosis and regeneration. Rilpivirine (RPV) is a widely used anti-HIV drug not reported to produce hepatotoxicity. We aimed to describe the potential hepatoprotective effects of RPV in different models of chronic liver injury, focusing on JAK-STAT signalling regulation. Design The effects of RPV on hepatic steatosis, inflammation and fibrogenesis were studied in a nutritional mouse model of non-alcoholic fatty liver disease, carbon tetrachloride-induced fibrosis and bile duct ligation-induced fibrosis. Primary human hepatic stellate cells (hHSC) and human cell lines LX-2 and Hep3B were used to investigate the underlying molecular mechanisms. Results RPV exerted a clear anti-inflammatory and antifibrotic effect in all the in vivo models of liver injury employed, and enhanced STAT3-dependent proliferation in hepatocytes and apoptosis in HSC through selective STAT1 activation. These results were reproduced in vitro; RPV undermined STAT3 activation and triggered STAT1-mediated pathways and apoptosis in HSC. Interestingly, this selective pro-apoptotic effect completely disappeared when STAT1 was silenced. Conditioned medium experiments showed that HSC apoptosis activated STAT3 in hepatocytes in an interleukin-6-dependent mechanism. Conclusion RPV ameliorates liver fibrosis through selective STAT1-dependent induction of apoptosis in HSC, which exert paracrinal effects in hepatocytes, thus promoting liver regeneration. RPV’s actions may represent an effective strategy to treat chronic liver diseases of different aetiologies and help identify novel therapeutic targets.

1 October 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
Nadezda ApostolovaNadezda Apostolova
Nadezda Apostolova
LGLeysa J. Gomez-Sucerquia
Leysa J. Gomez-Sucerquia
FAFernando Alegre
Fernando Alegre
HFHaryes A. Funes
Haryes A. Funes
Víctor M. VíctorVíctor M. Víctor
Víctor M. Víctor
JEJuan V. Esplugues
Juan V. Esplugues

9 May 2014 in The Journal of Infectious Diseases
Verified
Journal Article
Closed access
PDF file
HFHaryes A. Funes
Haryes A. Funes
Nadezda ApostolovaNadezda Apostolova
Nadezda Apostolova
FAFernando Alegre
Fernando Alegre
ABAna Blas-Garcia
Ana Blas-Garcia
AAAngeles Alvarez
Angeles Alvarez
JEJuan V. Esplugues
Juan V. Esplugues
Background. Neurological pathogenesis is associated with mitochondrial dysfunction and differences in neuronal/glial handling of oxygen and glucose. The main side effects attributed to efavirenz involve the CNS, but the underlying mechanisms are unclear.

9 July 2014 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
ABAna Blas-García
Ana Blas-García
MPMiriam Polo
Miriam Polo
FAFernando Alegre
Fernando Alegre
HFHaryes A. Funes
Haryes A. Funes
EMEsteban Martínez
Esteban Martínez
JEJuan V. Esplugues
Juan V. Esplugues
Objectives Growing evidence associates the non-nucleoside reverse transcriptase inhibitor efavirenz with several adverse events. Newer antiretrovirals, such as the integrase inhibitor raltegravir, the non-nucleoside reverse transcriptase inhibitor rilpivirine and the protease inhibitor darunavir, claim to have a better toxicological profile than efavirenz while producing similar levels of efficacy and virological suppression. The objective of this study was to determine the in vitro toxicological profile of these three new antiretrovirals by evaluating their effects on the mitochondrial and cellular parameters altered by efavirenz in hepatocytes and neurons. Methods Hep3B cells and primary rat neurons were treated with clinically relevant concentrations of efavirenz, darunavir, rilpivirine or raltegravir. Parameters of mitochondrial function, cytotoxicity and oxidative and endoplasmic reticulum stress were assessed using standard cell biology techniques. Results None of the new compounds altered the mitochondrial function of hepatic cells or neurons, while efavirenz decreased mitochondrial membrane potential and enhanced superoxide production in both cell types, effects that are known to significantly compromise the functioning of mitochondria, cell viability and, ultimately, cell number. Of the four drugs assayed, efavirenz was the only one to alter the protein expression of LC3-II, an indicator of autophagy, and CHOP, a marker of endoplasmic reticulum stress and the unfolded protein response. Conclusions Darunavir, rilpivirine and raltegravir do not induce toxic effects on Hep3B cells and primary rat neurons, which suggests a safer hepatic and neurological profile than that of efavirenz.

17 November 2017 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
FAFernando Alegre
Fernando Alegre
ÁMÁngela B Moragrega
Ángela B Moragrega
MPMiriam Polo
Miriam Polo
AMAlberto Marti‐Rodrigo
Alberto Marti‐Rodrigo
JEJuan V. Esplugues
Juan V. Esplugues
Nadezda ApostolovaNadezda Apostolova
Nadezda Apostolova
Background and Purpose: SQSTM1/p62 is a multifunctional, stress‐induced, scaffold protein involved in multiple cellular processes including autophagic clearance, regulation of inflammatory responses and redox homeostasis. Its altered function has been associated with different human pathologies, such as neurodegenerative, metabolic and bone diseases (down‐regulation), and cancerogenesis (up‐regulation). However, its role in the off‐target effects of clinically used drugs is still not understood.Experimental Approach: We evaluated the expression of p62 in cultured Hep3B cells and their derived ρ° cells (lacking mitochondria), along with markers of autophagy and mitochondrial dysfunction. The effects of efavirenz were compared with those of known pharmacological stressors, rotenone, thapsigargin and CCCP, and we also used transient silencing with siRNA and p62 overexpression. Western blotting, quantRT‐PCR and fluorescence microscopy were used to assay these effects and their underlying mechanisms.Key Results: In Hep3B cells, efavirenz augmented p62 protein content, an effect not observed in the corresponding ρ° cells. p62 up‐regulation followed enhanced SQSTM1 expression mediated through the transcription factor CHOP/DDIT3, while other well‐known regulators (NF‐kB and Nrf2) were not involved. Inhibition of autophagy with 3MA or with transient silencing of Atg5 did not affect SQSTM1 expression in efavirenz‐treated cells while p62 overexpression ameliorated the deleterious effect of efavirenz on cell viability.Conclusion and Implications: In our model, p62 exerted a specific, autophagy‐independent role and protected against efavirenz‐induced mitochondrial ROS generation and activation of the NLRP3 inflammasome. These findings add to the multifunctional nature of p62 and may help to understand the off‐target effects of clinically useful drugs.